Gensight biologics: After its surprise U-turn for its flagship product, biotech GenSight collapses on the stock market

(BFM Bourse) – The company has chosen to abandon the process to obtain marketing authorization for Lumevoq from the European Medicines Agency. GenSight plans to produce new clinical data, which could result in significant delays and additional costs. This is the big stock market setback of this Friday or even of the week. The biopharmaceutical…

Read More